D-0119-2026 Class II Ongoing

Recalled by ProRx LLC — Exton, PA

FDA drug recall D-0119-2026 was initiated by ProRx LLC on Oct 15, 2025 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is ongoing. Affected quantity: 2,805 vials.

Recall details

Product Type
Drugs
Report Date
Nov 5, 2025
Initiation Date
Oct 15, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2,805 vials

Product description

Semaglutide Injection, 5 mg/2 mL (2.5 mg/mL), 2mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-02

Reason for recall

Lack of Assurance of Sterility

Distribution pattern

TX and UT

Code information

Lot PRORX052125-4

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0119-2026
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0119-2026. Report a data issue: hello@regdatalab.com.